Company LXRX Nasdaq The Woodlands, TX Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops small molecule drug candidates for neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and cardiometabolic indications in discovery, preclinical, and clinical development stages.
2 Stories in coverage 22 approved Programs 1 Registered trial 6-K Aug 10 Latest SEC filing, period to Aug 10 Aug 6 Latest story
Timeline 2 Pipeline 2 Trials 1
All2 Regulatory1 Filings and people1
Pipeline by stage
Approved 2
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters The Woodlands, TX Incorporated Delaware Industry Pharmaceutical Preparations Formerly LEXICON PHARMACEUTICALS, INC./DE (to 2014); LEXICON GENETICS INC/TX (to 2007) Also known as LEXICON PHARMACEUTICALS, INC., LEXICON PHARMS INC, LXRX How the company describes itself Lexicon Pharmaceuticals develops small molecule drug candidates for neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and cardiometabolic indications in discovery, preclinical, and clinical development stages. source
